Why did Poly Medicure stock rally 11%?

Poly Medicure rallied ~11.19% on strong Q2 results (net profit Rs 918M), Medistream Italy acquisition completion, Citieffe Group proposal (EUR 18.8M), and ESOP allotment — all combined as strong growth signals.

Is Poly Medicure a good buy after the 11% rally?

Poly Medicure at P/E 52.12 is valuated richly. Pros: low debt (D/E 0.08), European expansion, consistent revenue growth. Cons: margin compression (27.4% to 25.8%), integration risk. Wait for Q3 margin recovery confirmation.

What is Poly Medicure share price target 2026?

Poly Medicure target price depends on Q3 results, Italy acquisition integration success, and sector growth. Track latest analyst targets and real-time data at currentaffair.today.

Breaking News Poly Medicure 11% Rally

Poly Medicure 11% Rally: Q2 Results, Italy Acquisition aur ESOP — Kya Ye Stock Short-Term Top Gainer Bana? (Real Data Analysis)

11 November 2025 by

Sk Jabedul Haque

Breaking News Poly Medicure 11% Rally - Cover Image

1️⃣ Momentum + Real Figures

Aaj (11 November 2025) Poly Medicure ne intraday me zabardast performance dikhaya — share price ₹2,070.60 tak upar gaya, matlab +₹208.30 / +11.19% jump (Groww data). Market ne is stock ko top gainer treat kiya. Ye move sirf random spike nahi tha — company ke Q2 results, acquisition updates, aur ESOP announcements ke combo se trigger hua.

in Markets

# Markets